Recombinant Tissue Factor Pathway Inhibitor Enhances the Binding of Factor Xa to Human Monocytes

Anguo Li; Alvin C.K. Chang; Glenn T. Peer; Tze-Chen Wun; Fletcher B. Taylor Jr.

doi:10.1055/s-0037-1615756

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 85(05): 830-836
DOI: 10.1055/s-0037-1615756

Review Article

Schattauer GmbH

Recombinant Tissue Factor Pathway Inhibitor Enhances the Binding of Factor Xa to Human Monocytes

Anguo Li

¹Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Searle-Monsanto Co. St. Louis, MO, USA

,

Alvin C.K. Chang

¹Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Searle-Monsanto Co. St. Louis, MO, USA

,

Glenn T. Peer

¹Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Searle-Monsanto Co. St. Louis, MO, USA

,

Tze-Chen Wun

¹Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Searle-Monsanto Co. St. Louis, MO, USA

,

Fletcher B. Taylor Jr.

¹Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Searle-Monsanto Co. St. Louis, MO, USA

› Institutsangaben

Abstract

Summary

Tissue factor pathway inhibitor (TFPI) is a kunitz-type inhibitor of activated factor X (Xa). TFPI was reported to mediate Xa binding to a few of carcinoma cell lines. In this study it was observed that the Xa activity associated with human peripheral blood mononuclear cells (PBMC) incubated with Xa in the presence of recombinant TFPI (rTFPI) was much higher than with Xa alone. Xa activity on PBMC was also observed after whole blood was incubated with pre-formed Xa/TFPI complex. Further studies with flow cytometric analysis demonstrate that rTFPI enhances the binding of Xa to human monocytes. Western blot analysis showed that rTFPI was cleaved into a few of fragments after its incubation with monocytes either in the presence or absence of Xa. Based on these results and the observations reported by others, we speculate that Xa/TFPI complex may bind to human monocytes by a yet unidentified mechanism. The recovery of Xa activity from Xa/TFPI complex on PBMC may be related to the cleavage of rTFPI by Xa and/or monocyte proteases. This observation suggests a new mechanism by which monocytes become procoagulant in some pathological conditions in addition of the well known tissue factor expression on proinflammatic monocytes.

Keywords

TFPI - factor X (Xa) - rTFPI

Volltext

Referenzen

References
1 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317.
2 Altieri DC, Stamnes SJ. Protease-dependent T cell activation: Ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation. Cellular Immunology 1994; 155: 372.
3 Jones A, Geczy CL. Thrombin and factor Xa enhance the production of interleukin-1. Immunology 1990; 71: 236.
4 Tracy PB, Rohrbach MS, Mann KG. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 1983; 258: 7264.
5 Rogers GM, and Shuman MA. Characterization of the interaction between factor Xa and bovine aortic endothelial cells. Biochim Biophys Acta 1985; 844: 320.
6 Stern DM, Nawroth PP, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci U. S. A. 1985; 82: 2523.
7 Altieri DC, Edgington TS. Identification of effector cell protease receptor-1 A leukocyte-distributed receptor for the serine protease factor Xa. J Immunol 1990; 145: 246.
8 Worfolk LA, Robinson RA, Tracy PB. Factor Xa interacts with two sites on monocytes with different functional activities. Blood 1992; 80: 1989.
9 Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
10 Sakai T, Kisiel W. Binding of Human factors X and Xa to HepG2 and J82 human tumor cell lines Evidence that factor Xa binds to tumor cells independent of factor Va. J Biol Chem 1990; 265: 9105.
11 Kazama Y, Komiyama Y, Kisiel W. Tissue factor pathway inhibitor and protease nexon-1 are major factor Xa binding proteins on the HepG2 cell surface. Blood 1993; 81: 676.
12 Ho G, Toomey RJ, Broze Jr JG, Schwartz LA. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor. J Biol Chem 1996; 271 (Suppl. 16) 9497.
13 Ho G, Broze Jr GJ, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem 1997; 272 (Suppl. 27) 16838-44.
14 Diaz-Collier JA, Palmier MO, Kretzmer KK, Bishop BF, Combs RG, Obukowicz MG, Frazier RB, Bild GS, Joy WD, Hill SR, Duffin ME, Gustafson ME, Junger JD, Grabner RW, Galluppi GR, Wun T-C. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 1994; 71 (Suppl. 03) 339-46.
15 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505.
16 Li A, Chang ACK, Peer GT, Hinshaw LB, Taylor Jr FB. Comparison of capacity of rhTNF- and Escherichia. coli to induce procoagulant activity by baboon mononuclear cells in vivo and in vitro . Shock 1996; 5: 274.
17 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335.
18 Novonty WF, Brown SG, Miletich JP, Rader DJ, Broze Jr GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387.
19 Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coag Fibrinol 1994; 5: 819.
20 Morrissey JH, Fair DS, Edgington TS. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988; 52: 247.
21 Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001.
22 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JH, Broze Jr GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518.
23 Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994; 33: 12686.
24 Altieri DC, Edgington TS. Sequential receptor cascade for coagulation proteins on monocytes Constitutive biosynthesis and functional prothrombinase activity of a membrane form of factor V/Va. J Biol Chem 1989; 264: 2969.
25 Nykjær A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thøgersen HC, Munch M, Andreasen PA, Gliemann J. Purified α₂-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that α₂-macroglobulin receptor mediates cellular degradation of urokinase-bound complex. J Biol Chem 1992; 267: 14543.
26 Warshawsky I, Broze Jr GJ, Schwartz AL. The Low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664.
27 Warshawsky I, Herz J, Broze Jr GJ, Schwartz AL. The low-density lipo-protein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem 1996; 271 (Suppl. 42) 25873-9.
28 Valentin S, Schousboe I. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Thromb Haemost 1996; 75 (Suppl. 05) 796-800.
29 Lindhout T, Salemink I, Valentin S, Willems GM. Tissue factor pathway inhibitor: regulation of its inhibitory activity by phospholipid surfaces. Haemostasis 1996; 26 (Suppl. 04) 89-97.
30 Sevinsky JR, Rao VM, Ruf W. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133 (Suppl. 02) 293.
31 Mast AE, Higuchi DA, Huang ZF, Warshawsky I, Schwartz AL, Broze Jr GJ. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J 327 1997; (Pt 2) 577-83.
32 Salemink I, Franssen J, Willems GM, Hemker HC, Li A, Wun T-C, and Lindhout T. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 1998; 80 (Suppl. 02) 273.
33 Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67 (Suppl. 05) 537-41.
34 Higuchi DA, Wun TC, Likert KM, Broze Jr GJ. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79 (Suppl. 07) 1712-9.
35 Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, Kotzsch M, Schomig A. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17 (Suppl. 12) 3399-405.
36 Leatham EW, Bath PM, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73 (Suppl. 01) 10-3.